カナダ糖尿病協会によると、2022年の新しい数値は、カナダでの糖尿病率が引き続き上昇傾向にあり、平坦化や減少の兆候がないことを示しています。糖尿病は、これまで以上に多くのカナダ人に影響を与え続けています。新しい糖尿病の数値は、国における糖尿病の着実かつ継続的な増加を示しており、1170万人のカナダ人が糖尿病または前糖尿病を抱えており、570万人以上のカナダ人が診断された糖尿病（1型または2型糖尿病）を持っています。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

  • 4.3 市場の抑制要因

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 サプライヤーの交渉力

    • 4.4.2 消費者の交渉力

    • 4.4.3 新規参入の脅威

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション

  • 5.1 製品

    • 5.1.1 ランタス

    • 5.1.2 レベミル

    • 5.1.3 東條（とうじょう

    • 5.1.4 トレシーバ

    • 5.1.5 バサグラー

  • 5.2 地域別

    • 5.2.1 北米

      • 5.2.1.1 米国
      • 5.2.1.2 カナダ
      • 5.2.1.3 その他の北米

    • 5.2.2 ヨーロッパ

      • 5.2.2.1 ドイツ
      • 5.2.2.2 スペイン
      • 5.2.2.3 イタリア
      • 5.2.2.4 フランス
      • 5.2.2.5 英国
      • 5.2.2.6 ロシア
      • 5.2.2.7 その他のヨーロッパ

    • 5.2.3 アジア太平洋

      • 5.2.3.1 日本
      • 5.2.3.2 中国
      • 5.2.3.3 オーストラリア
      • 5.2.3.4 インド
      • 5.2.3.5 韓国
      • 5.2.3.6 マレーシア
      • 5.2.3.7 インドネシア
      • 5.2.3.8 タイ
      • 5.2.3.9 フィリピン
      • 5.2.3.10 ベトナム
      • 5.2.3.11 その他のアジア太平洋

    • 5.2.4 ラテンアメリカ

      • 5.2.4.1 ブラジル
      • 5.2.4.2 メキシコ
      • 5.2.4.3 その他のラテンアメリカ

    • 5.2.5 中東・アフリカ

      • 5.2.5.1 南アフリカ
      • 5.2.5.2 サウジアラビア
      • 5.2.5.3 オマーン
      • 5.2.5.4 エジプト
      • 5.2.5.5 イラン
      • 5.2.5.6 その他の中東・アフリカ

• 6 市場指標

  • 6.1 1型糖尿病人口

  • 6.2 2型糖尿病人口

• 7 競合情勢

  • 7.1 企業プロファイル

    • 7.1.1 Novo Nordisk AS

    • 7.1.2 Sanofi Aventis

    • 7.1.3 Eli Lilly

    • 7.1.4 Biocon

    • 7.1.5 Julphar

    • 7.1.6 Wockhardt

    • 7.1.7 Pfizer

      • 7.1.7.1 その他の主要市場プレイヤー

  • 7.2 Company Share Analysis

    • 7.2.1 Novo Nordisk AS

    • 7.2.2 Sanofi Aventis

    • 7.2.3 Eli Lilly

• 8 市場機会と今後の動向

The Basal Insulin Market size is estimated at USD 273.68 million in 2024, and is expected to reach USD 344.33 million by 2029, growing at a CAGR of 4.70% during the forecast period (2024-2029).

The market is estimated to reach a value of more than USD 4.9 billion during the forecast period.

The COVID-19 pandemic has substantially impacted the Global Basal Insulin Market. People with diabetes have a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of diabetes care productshave taken care during COVID-19 to deliver diabetes care products to diabetes patients with the help of local governments.

Novo Nordisk stated on its website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and the intake of medicine has increased. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers paving the way for cost-effective alternatives such as biosimilars and combination insulins.

The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in developed countries are indications of the increasing usage of diabetic care products. Leading manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness negative growth over the analysis period.

Basal Insulin Market Trends

Increasing diabetes prevalence

The diabetes population is expected to rise by more than 1.9% over the forecast period.

According to the International Diabetes Federation, the adult diabetes population in 2021 was approximately 537 million, which will increase by 643 million in 2030. Obesity is considered one of the major factors contributing to the disease, primarily Type 2 diabetes. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Type 2 diabetes is increasingly prevalent and associated with an increased cardiovascular and renal disease risk.

The market players are adopting various strategies such as collaborations, partnerships, mergers, acquisitions, and expansions for new products to increase market share. For instance, Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). However, the companies are working on various innovations, such as Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for treating type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus promising to transform type-1 management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on developing oral drug delivery systems, is working to bring the first oral insulin.

Owing to the factors above, the studied market is anticipated to be impacted over the analysis period.

North America holds the highest market share in the Global Basal Insulin (Long-acting Insulin) Market in the current year

North America holds the highest market share in the Global Basal Insulin (Long-acting Insulin) Market in the current year and is expected to witness a CAGR of about 0.8% over the forecast period.

The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults live with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color; those who live in rural areas; and those with less education, lower incomes, and lower health literacy.

According to Diabetes Canada, new 2022 figures show the continued rising trend of diabetes rates in Canada with no signs of leveling or decreasing. Diabetes continues to affect more Canadians than ever before. The new diabetes figures show a steady, continued increase in diabetes in the country, with 11.7 million Canadians living with diabetes or prediabetes; more than 5.7 million Canadians are living with diagnosed diabetes (type 1 or type 2 diabetes).

Diabetes is associated with many health complications. Patients with diabetes require many daily corrections to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be difficult without multiple daily insulins or insulin therapy injections.

The disease's growing incidence, prevalence, and progressive nature have encouraged treatment options for diabetic patients. The American Diabetes Association also helps with the costs of insulin and diabetes medication. Medicare drug plans cover insulin not used in an insulin pump and other drugs necessary to treat diabetes. In addition to providing prescription drug coverage, Medicare Part D plans may cover supplies necessary to inject insulin, including syringes, needles, alcohol swabs, and gauze.

Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.

Basal Insulin Industry Overview

The Global Basal Insulin (Long-acting Insulin) Market is consolidated, with a few major manufacturers having a global market presence and occupying a major share, like Eli Lilly, Boehringer Ingelheim, Sanofi, Biocon, etc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

  • 4.3 Market Restraints

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Bargaining Power of Suppliers

    • 4.4.2 Bargaining Power of Consumers

    • 4.4.3 Threat of New Entrants

    • 4.4.4 Threat of Substitute Products and Services

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION

  • 5.1 Products

    • 5.1.1 Lantus

    • 5.1.2 Levemir

    • 5.1.3 Toujeo

    • 5.1.4 Tresiba

    • 5.1.5 Basaglar

  • 5.2 Geography

    • 5.2.1 North America

      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Rest of North America

    • 5.2.2 Europe

      • 5.2.2.1 Germany
      • 5.2.2.2 Spain
      • 5.2.2.3 Italy
      • 5.2.2.4 France
      • 5.2.2.5 United Kingdom
      • 5.2.2.6 Russia
      • 5.2.2.7 Rest of Europe

    • 5.2.3 Asia-Pacific

      • 5.2.3.1 Japan
      • 5.2.3.2 China
      • 5.2.3.3 Australia
      • 5.2.3.4 India
      • 5.2.3.5 South Korea
      • 5.2.3.6 Malaysia
      • 5.2.3.7 Indonesia
      • 5.2.3.8 Thailand
      • 5.2.3.9 Philippines
      • 5.2.3.10 Vietnam
      • 5.2.3.11 Rest of Asia-Pacific

    • 5.2.4 Latin America

      • 5.2.4.1 Brazil
      • 5.2.4.2 Mexico
      • 5.2.4.3 Rest of Latin America

    • 5.2.5 Middle East and Africa

      • 5.2.5.1 South Africa
      • 5.2.5.2 Saudi Arabia
      • 5.2.5.3 Oman
      • 5.2.5.4 Egypt
      • 5.2.5.5 Iran
      • 5.2.5.6 Rest of Middle East and Africa

• 6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population

  • 6.2 Type-2 Diabetes Population

• 7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles

    • 7.1.1 Novo Nordisk AS

    • 7.1.2 Sanofi Aventis

    • 7.1.3 Eli Lilly

    • 7.1.4 Biocon

    • 7.1.5 Julphar

    • 7.1.6 Wockhardt

    • 7.1.7 Pfizer

      • 7.1.7.1 Other Key Market Players

  • 7.2 Company Share Analysis

    • 7.2.1 Novo Nordisk AS

    • 7.2.2 Sanofi Aventis

    • 7.2.3 Eli Lilly

• 8 MARKET OPPORTUNITIES AND FUTURE TRENDS